Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 3.96
ARRY's Cash-to-Debt is ranked lower than
65% of the 1046 Companies
in the Global Biotechnology industry.

( Industry Median: 55.72 vs. ARRY: 3.96 )
Ranked among companies with meaningful Cash-to-Debt only.
ARRY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.49  Med: 1.67 Max: No Debt
Current: 3.96
0.49
No Debt
Equity-to-Asset 0.52
ARRY's Equity-to-Asset is ranked lower than
69% of the 767 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ARRY: 0.52 )
Ranked among companies with meaningful Equity-to-Asset only.
ARRY' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.55  Med: 0.22 Max: 0.93
Current: 0.52
-1.55
0.93
Debt-to-Equity 0.44
ARRY's Debt-to-Equity is ranked lower than
64% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 0.26 vs. ARRY: 0.44 )
Ranked among companies with meaningful Debt-to-Equity only.
ARRY' s Debt-to-Equity Range Over the Past 10 Years
Min: -18.96  Med: -0.69 Max: 18.79
Current: 0.44
-18.96
18.79
Debt-to-EBITDA -0.87
ARRY's Debt-to-EBITDA is ranked lower than
99.99% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 1.94 vs. ARRY: -0.87 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ARRY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -13.41  Med: -1.42 Max: 4.6
Current: -0.87
-13.41
4.6
Piotroski F-Score: 3
Altman Z-Score: 6.99
Beneish M-Score: -3.20
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -85.96
ARRY's Operating Margin % is ranked higher than
52% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -105.96 vs. ARRY: -85.96 )
Ranked among companies with meaningful Operating Margin % only.
ARRY' s Operating Margin % Range Over the Past 10 Years
Min: -410.11  Med: -63.65 Max: 6.34
Current: -85.96
-410.11
6.34
Net Margin % -98.51
ARRY's Net Margin % is ranked lower than
51% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -92.13 vs. ARRY: -98.51 )
Ranked among companies with meaningful Net Margin % only.
ARRY' s Net Margin % Range Over the Past 10 Years
Min: -511.63  Med: -83.68 Max: 18.05
Current: -98.51
-511.63
18.05
ROE % -122.22
ARRY's ROE % is ranked lower than
80% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: -39.05 vs. ARRY: -122.22 )
Ranked among companies with meaningful ROE % only.
ARRY' s ROE % Range Over the Past 10 Years
Min: -3933.07  Med: -132.15 Max: 110.67
Current: -122.22
-3933.07
110.67
ROA % -38.63
ARRY's ROA % is ranked lower than
54% of the 1052 Companies
in the Global Biotechnology industry.

( Industry Median: -32.93 vs. ARRY: -38.63 )
Ranked among companies with meaningful ROA % only.
ARRY' s ROA % Range Over the Past 10 Years
Min: -99.03  Med: -51.46 Max: 5.6
Current: -38.63
-99.03
5.6
ROC (Joel Greenblatt) % -1604.54
ARRY's ROC (Joel Greenblatt) % is ranked lower than
67% of the 1014 Companies
in the Global Biotechnology industry.

( Industry Median: -432.52 vs. ARRY: -1604.54 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ARRY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1410.82  Med: -321.97 Max: 297.05
Current: -1604.54
-1410.82
297.05
3-Year Revenue Growth Rate 39.40
ARRY's 3-Year Revenue Growth Rate is ranked higher than
84% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ARRY: 39.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ARRY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -35.9  Med: -2.2 Max: 39.8
Current: 39.4
-35.9
39.8
3-Year EBITDA Growth Rate 2.90
ARRY's 3-Year EBITDA Growth Rate is ranked higher than
51% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. ARRY: 2.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ARRY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -66.3  Med: 2.7 Max: 105.1
Current: 2.9
-66.3
105.1
3-Year EPS without NRI Growth Rate 1.40
ARRY's 3-Year EPS without NRI Growth Rate is ranked higher than
52% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. ARRY: 1.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ARRY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -50.5  Med: 1.4 Max: 55.7
Current: 1.4
-50.5
55.7
GuruFocus has detected 4 Warning Signs with Array BioPharma Inc ARRY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ARRY's 30-Y Financials

Financials (Next Earnings Date: 2018-05-10)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

ARRY Guru Trades in Q1 2017

Caxton Associates 15,900 sh (New)
Ken Fisher 78,014 sh (+18.76%)
Steven Cohen 500,000 sh (unchged)
Steven Cohen 1,277,900 sh (-18.64%)
» More
Q2 2017

ARRY Guru Trades in Q2 2017

Paul Tudor Jones 73,373 sh (New)
Jim Simons 990,441 sh (New)
Steven Cohen 2,406,000 sh (+88.28%)
Ken Fisher 134,180 sh (+71.99%)
Caxton Associates Sold Out
» More
Q3 2017

ARRY Guru Trades in Q3 2017

Louis Moore Bacon 100,000 sh (New)
Steven Cohen 9,008,999 sh (+274.44%)
Paul Tudor Jones 75,184 sh (+2.47%)
Ken Fisher 134,180 sh (unchged)
Jim Simons Sold Out
» More
Q4 2017

ARRY Guru Trades in Q4 2017

Jim Simons 712,671 sh (New)
Pioneer Investments 54,900 sh (New)
Ken Fisher 161,433 sh (+20.31%)
Steven Cohen 1,020,900 sh (unchged)
Louis Moore Bacon Sold Out
Steven Cohen 5,712,626 sh (-36.59%)
Paul Tudor Jones 12,834 sh (-82.93%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ARRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-12-31 Add 20.31%$10.26 - $12.97 $ 16.9849%161,433
Ken Fisher 2017-06-30 Add 71.99%$6.96 - $9.07 $ 16.98107%134,180
Ken Fisher 2017-03-31 Add 18.76%$8.56 - $12.56 $ 16.9860%78,014
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:XKRX:086900, SHSE:603233, NAS:CORT, XTER:MOR, SZSE:300009, NAS:GBT, SZSE:002603, NAS:IMMU, SZSE:300347, HKSE:00570, SHSE:600161, NAS:FOLD, NAS:HALO, NAS:PBYI, NAS:CLVS, NAS:LOXO, NAS:ANAB, NYSE:EBS, LSE:ABC, XSWX:GALE » details
Traded in other countries:AR2.Germany,
Headquarter Location:USA
Array BioPharma Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.

Array BioPharma Inc was incorporated in Delaware on February 6, 1998. It is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Its clinical stage drugs include Binimetinib, Encorafenib, Selumetinib, Tucatinib/ONT-380, ARRY-382, LOXO-292 and LOXO-195 among others. The company has geographical presence in North America, Europe and Asia Pacific.

Top Ranked Articles about Array BioPharma Inc

Array BioPharma To Present At The LEERINK Partners 7th Annual Global Healthcare Conference
Array BioPharma Reports Financial Results For The Second Quarter of Fiscal 2018
Encorafenib and Binimetinib Combination Treatment Demonstrates 33.6 Month Median Overall Survival (OS) in Patients with BRAF-Mutant Melanoma in Phase 3 COLUMBUS Trial
Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2018 On February 6, 2018
Combination of Encorafenib, Binimetinib and Cetuximab Demonstrated an 8 Month Median Progression-Free Survival in BRAF-Mutant Colorectal Cancer in Updated Safety Lead-In Results from BEACON Phase 3 Trial
FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Array BioPharma Inc. (Nasdaq: ARRY) To Contact The Firm
Array BioPharma to Present Updated Phase 3 BEACON CRC Safety Lead-In Results of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant Colorectal Cancer at the 2018 Gastrointestinal Cancers Symposium
ARRY LOSS ALERT: Rosen Law Firm Reminds Array Biopharma Inc. Investors of Important January 22 Deadline in Class Action– ARRY
The Klein Law Firm Reminds Shareholders of a Class Action on Behalf of Array Biopharma Inc. Shareholders and a Lead Plaintiff Deadline of January 22, 2018 (ARRY)
Array BioPharma To Present At The Annual J.P. Morgan Healthcare Conference

Ratios

vs
industry
vs
history
PB Ratio 14.55
ARRY's PB Ratio is ranked lower than
86% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. ARRY: 14.55 )
Ranked among companies with meaningful PB Ratio only.
ARRY' s PB Ratio Range Over the Past 10 Years
Min: 3.52  Med: 16.25 Max: 135.59
Current: 14.55
3.52
135.59
PS Ratio 21.88
ARRY's PS Ratio is ranked lower than
63% of the 731 Companies
in the Global Biotechnology industry.

( Industry Median: 11.11 vs. ARRY: 21.88 )
Ranked among companies with meaningful PS Ratio only.
ARRY' s PS Ratio Range Over the Past 10 Years
Min: 1.44  Med: 7.65 Max: 24.4
Current: 21.88
1.44
24.4
EV-to-EBIT -25.77
ARRY's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.83 vs. ARRY: -25.77 )
Ranked among companies with meaningful EV-to-EBIT only.
ARRY' s EV-to-EBIT Range Over the Past 10 Years
Min: -44  Med: -6 Max: 320.9
Current: -25.77
-44
320.9
EV-to-EBITDA -26.24
ARRY's EV-to-EBITDA is ranked lower than
99.99% of the 285 Companies
in the Global Biotechnology industry.

( Industry Median: 20.69 vs. ARRY: -26.24 )
Ranked among companies with meaningful EV-to-EBITDA only.
ARRY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -76.5  Med: -6.5 Max: 165.9
Current: -26.24
-76.5
165.9
EV-to-Revenue 23.11
ARRY's EV-to-Revenue is ranked lower than
61% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 12.21 vs. ARRY: 23.11 )
Ranked among companies with meaningful EV-to-Revenue only.
ARRY' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.1  Med: 7.7 Max: 27.9
Current: 23.11
2.1
27.9
Current Ratio 6.17
ARRY's Current Ratio is ranked higher than
65% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. ARRY: 6.17 )
Ranked among companies with meaningful Current Ratio only.
ARRY' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 3 Max: 7.86
Current: 6.17
0.81
7.86
Quick Ratio 6.17
ARRY's Quick Ratio is ranked higher than
66% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.86 vs. ARRY: 6.17 )
Ranked among companies with meaningful Quick Ratio only.
ARRY' s Quick Ratio Range Over the Past 10 Years
Min: 0.81  Med: 2.96 Max: 7.55
Current: 6.17
0.81
7.55
Days Sales Outstanding 78.69
ARRY's Days Sales Outstanding is ranked lower than
62% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: 65.03 vs. ARRY: 78.69 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARRY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.61  Med: 50.33 Max: 497.21
Current: 78.69
4.61
497.21
Days Payable 93.34
ARRY's Days Payable is ranked higher than
63% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 59.19 vs. ARRY: 93.34 )
Ranked among companies with meaningful Days Payable only.
ARRY' s Days Payable Range Over the Past 10 Years
Min: 37.58  Med: 76.12 Max: 159.87
Current: 93.34
37.58
159.87

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.10
ARRY's 3-Year Average Share Buyback Ratio is ranked higher than
62% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. ARRY: -9.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARRY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -111.3  Med: -11.65 Max: -4.2
Current: -9.1
-111.3
-4.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 17.68
ARRY's Price-to-Net-Cash is ranked lower than
75% of the 566 Companies
in the Global Biotechnology industry.

( Industry Median: 7.67 vs. ARRY: 17.68 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ARRY' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.76  Med: 7.43 Max: 141.11
Current: 17.68
2.76
141.11
Price-to-Net-Current-Asset-Value 15.16
ARRY's Price-to-Net-Current-Asset-Value is ranked lower than
76% of the 694 Companies
in the Global Biotechnology industry.

( Industry Median: 7.04 vs. ARRY: 15.16 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ARRY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.24  Med: 7.03 Max: 418.5
Current: 15.16
2.24
418.5
Price-to-Tangible-Book 14.55
ARRY's Price-to-Tangible-Book is ranked lower than
80% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 5.30 vs. ARRY: 14.55 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ARRY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.14  Med: 4.51 Max: 123.09
Current: 14.55
1.14
123.09
Price-to-Median-PS-Value 2.87
ARRY's Price-to-Median-PS-Value is ranked lower than
88% of the 629 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. ARRY: 2.87 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ARRY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.19  Med: 0.9 Max: 2.89
Current: 2.87
0.19
2.89
Earnings Yield (Greenblatt) % -3.88
ARRY's Earnings Yield (Greenblatt) % is ranked higher than
59% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -7.37 vs. ARRY: -3.88 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ARRY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -95.2  Med: -14 Max: 5.1
Current: -3.88
-95.2
5.1

More Statistics

Revenue (TTM) (Mil) $139.02
EPS (TTM) $ -0.78
Beta2.35
Short Percentage of Float9.04%
52-Week Range $6.73 - 18.24
Shares Outstanding (Mil)207.64

Analyst Estimate

Jun18 Jun19
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -1.19 -0.51
EPS without NRI ($) -1.19 -0.51
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}